APOE is a potential modifier gene in an autosomal dominant form of frontotemporal dementia (IBMPFD)

Area of Science:

• Genetics
• Neurology
• Bone Diseases

Background:

• Inclusion-body myopathy, Paget's disease of bone, and frontotemporal dementia (IBMPFD) is an adult-onset autosomal dominant disorder.
• Mutations in the valosin-containing protein (VCP) gene cause IBMPFD, with variable penetrance for different clinical manifestations.
• Modifier genes may influence the reduced penetrance of frontotemporal dementia (FTD) in IBMPFD.

Purpose of the Study:

• To investigate the role of apolipoprotein-E (APOE) as a modifier gene in IBMPFD, specifically its association with FTD.
• To evaluate the impact of APOE genotype on FTD penetrance within IBMPFD families.

Main Methods:

• Analysis of APOE genotype data from 174 members across 15 IBMPFD families.
• Logistic regression models were used to assess the association between APOE genotype and FTD, controlling for relevant covariates.

Main Results:

• APOE 4 genotype showed a significant association with FTD in IBMPFD patients (P=0.0002).
• Myopathy (P=0.0006) and age (P=0.01) were also associated with FTD.
• No significant association was found between FTD and MAPT H2 haplotype or gender.

Conclusions:

• The APOE 4 genotype is linked to the development of frontotemporal dementia in individuals with IBMPFD.
• These findings suggest a potential genetic interaction between APOE and VCP in the pathogenesis of FTD within IBMPFD.
• Further research is warranted to elucidate the molecular mechanisms underlying this association.